chrisvoncsefalvay/vaers-outcomes huggingface dataset:
other people are going through this/he had went to the doctor who tried to tell him it was alopecia; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ALOPECIA (non-serious), outcome "unknown", described as "other people are going through this/he had went to the doctor who tried to tell him it was alopecia".  Additional information: Consumer reported he has had the first two doses and he is having symptoms because of that COVID shot. He says he knows it is from the COVID shot, though he had went to the doctor who tried to tell him it was alopecia, but he knows the COVID shot would have given him a blood disease that gave him alopecia.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
The pt developed a fever, chills, nausea and vomiting. Dx'd with labyrinthitis and rx'd meclizine and compazine.
Vaccine given 9/26/09. Patient complained of Diarrhea on 9/26/09. Started on 10/2/09. Patient seen in ER. On 10/4/09. Patient said Doctor gave steroids dose pack, said Doctor told her possible allergy to component in shot. Doctor also questioned. Patient about possible chicken pox. Patient going to see family MD. 10/05/09.
Left arm swelling (deltoid region) warm to touch, no discoloration, able to move with some discomfort, told to give Ibuprofen and cold compresses
It has been nearly 3 years since last date of menstruation. Thus, I am considered to be menopausal.  I received my first Pfizer vaccine on 9/2/21. Approximately one week after, I began spotting. I received my second vaccine on 9/23/21. Approximately 2 weeks later, I began a full period.
Arm soreness on day of and day after the vaccine.  Fatigue and low energy on day of and day after.  Minor dizziness/lightheadedness when standing or moving around on day of (and day after with prolonged standing). Rested and avoided exertion on day of and after to ?treat? adverse events.
Pt presented for COVID-19 vaccine on 6/24/21 at community event. Pt filled out paperwork stating that this was his 1st COVID-19 Vaccine and he chose to get Moderna. Pt presented to the clinic on 8/2/21 for his 2nd dose of Moderna. Pharmacy staff received email from on 8/27/21 to look into pt as he may have received too many doses. Reviewed and noted that pt had also received the Pfizer COVID-19 Vaccine on 4/22/21 and 5/13/21 at another facility. Tried contacting pt to discuss if he had any side effects, however pt is currently incarcerated and I was unable to get ahold of him.
Patient was seated for 15 minutes following the vaccination and when he got up to retrieve his vaccination record card he passed out onto the floor. He was attended to by the nurse on staff as well as myself. Reported no pain, knew his name and where he was. Stated no history of seizures and was not diabetic. Stated he has not eaten today, only a Starbucks. We got him up to a chair after a few minutes and attempted to take his blood pressure. He passed out a second time and we got him to the floor. He was alert shortly after getting him to a laying position. Ambulance was called and he was taken to be checked out.  Patient did return the next day to thank us and let us know he had a CT and labs done. His physician thought it was a vasovagal episode. He is to follow up with his primary physician soon.
Severe cramping, diarrhea, vomiting, fatigue like I have never experienced before. This should not be injected into humans
Site: Bruising at Injection Site-Severe, Site: Pain at Injection Site-Severe, Site: Swelling at Injection Site-Severe, Additional Details: Patient immediately after receiving of vaccine experienced bleeding; a cotton ball was applied, and patient's arm was cleansed with alcohol swaps. Bleeding stopped, patient stated they felt okay after a 15 minute monitoring period, and went home after. 09/19/2021 called and reported bruising and that the arm felt hot to the touch. Patient was recommended to contact a health care provider to be checked out with symptoms, and that we would be checking back to monitor how patient was doing.
Received immunizations on Friday. Pt c/o it itching Friday, fever & redness & warmth was noted. Sat. he said his mom gave him ADVIL & put NEOSPORIN oint. on area.
Incorrect dose given. Patient received the Covid-19 Pfizer vaccine for those 6 months-4 years of age. He should have received the Covid-19 Pfizer Monovalent vaccine for those 5-11 years of age.
Day after vaccine I had extreme nausea and head ache. Following day my lips went numb. Woke up the next day to Bell?s palsy (ER diagnosed) steroids seem to be helping. Currently still taking them.
So I started with cold symptoms of cough runny nose and sore throat on 12/20/2022 in the evening. On the morning of 12/21/2022 I took a COVID-19 test which was negative my partners however was positive so I called my doctor and she suggested I go to the nearest ER. At the ER I was tested Influenza COVID-19 and Strep throat all of which returned negative. My partners tests all returned negative except he was positive for COVID-19, all his vaccines were Pfizer all mine were Moderna. I was not given any medications PAXLOVID may interact with my current medications.
Diarrhea developed 24 hours after the vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of DIARRHOEA (Diarrhea developed 24 hours after the vaccine) in a 30-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7173B) for COVID-19 prophylaxis.     Previously administered products included for COVID-19 prophylaxis: Moderna COVID-19 Vaccine (First Moderna Covid-19 Monovalent booster dose, lot number 939902, Anatomica location-Left arm.) on 09-Sep-2021, Moderna COVID-19 Vaccine (Second Monovalent Moderna Covid-19 bivalent vaccine, lot number 022J21A expiration date 24-APR-22 and Anatomical location- Left arm. ) on 07-Feb-2022. Past adverse reactions to the above products included No adverse event with Moderna COVID-19 Vaccine and Moderna COVID-19 Vaccine.    On 12-Jun-2023, the patient received third dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 12-Jun-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced DIARRHOEA (Diarrhea developed 24 hours after the vaccine). The patient was treated with GATIFLOXACIN (GATOR) at an unspecified dose and frequency. At the time of the report, DIARRHOEA (Diarrhea developed 24 hours after the vaccine) had not resolved.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   Patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine was unknown. Concomitant medication details not reported by the reporter. It was reported that the patient had diarrhea each day since June 12, 2023. The patient was able to conduct daily of life activities such as going to work. Patient tried Immodium, Pepto-Bismol, and these medications were not working. The patient was taking energy drink for hydration. No dietary changes were noted in the patient during the time after the Moderna Covid-19 bivalent booster dose.
Information has been received from a registered nurse referring to an unspecified number of patients of unknown age and gender. Information regarding concurrent condition or medical history was unknown. On unknown dates, the patients each were vaccinated with a dose of improperly stored VAQTA (lot # N005605 with expiration date 08-APR-2018 and lot # M039202 with expiration date 11-MAR-2018, route and dose unknown) for prophylaxis. No adverse effects were reported. The vaccines were stored under temperature 9-25 degrees Celsius with time frame 1 hour and 13 minutes. There was no previous temperature excursion. No data logger involved. This is one of several reports from the same reporter. Sender's Comments: US-009507513-1707USA008913: US-009507513-1707USA009010: US-009507513-1707USA009011: US-009507513-1707USA009013: US-009507513-1707USA009014.
Varicella disease despite 2 varicella vaccines. Just to note, sibling had the varivax vaccine two weeks ago.
Erectile dysfunction within a week of 2nd dose which cleared up after 3-4 weeks; lateral neuropathy in right big toe and upper left thigh within 2 months; dribbling after urination; trouble urinating; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 48-year-old male patient received bnt162b2 (BNT162B2), dose 2 via an unspecified route of administration, administered in Arm Left on 24May2021 08:45 (Batch/Lot Number: ER8731) as single dose for covid-19 immunisation at the age of 48-year-old.  Medical history included allergy to mango skin, cashews, poison ivy. The patient previously received bnt162b2 dose 1 administered in Arm Left on 03May2021 10:30 (Batch/Lot Number: EW0158) as single dose for covid-19 immunisation at the age of 48-year-old. Concomitant medications included atorvastatin calcium; aspirin [acetylsalicylic acid]; vitamin D3. On 30May2021 14:00, the patient experienced erectile dysfunction which cleared up after 3-4 weeks, dribbling after urination, lateral neuropathy in right big toe and upper left thigh, trouble urinating. Outcome of erectile dysfunction was recovered in 2021, outcome of other events as not recovered. The events resulted Doctor or other healthcare professional office/clinic visit. Treatment received for erectile dysfunction included Sildenafil. The patient didn't receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19, and since the vaccination the patient hasn't been tested for COVID-19.  Follow-up attempts are completed. No further information is expected.
Fever Chills Sensative teeth Hair loss Fatigue Joint and muscle pain Headache
Information has been received from a physician concerning a 2 year old female with no medical history or allergies who on 03-Aug-2008 was vaccinated with PROQUAD. There were no concomitant medications. It was reported the patient developed what the physician considered to be a "typical case of breakthrough". On 10-Sep-2008 the patient experienced "mild systemic symptoms" and less than 50 lesions. The patient was brought to for medical attention at the physician's office. The physician did not feel further testing of the child was necessary. It was reported the patient  had not recovered from "typical case of breakthrough", "mild systemic symptoms" and less than 50 lesions. No further information is available. A product quality complaint was not involved. Additional information has been requested.
Treated for a tick bite with doxycycline on 3/26/2021 diagnosis of anaplasmosis. Developed Progressive focal motor weakness   Reflex abnormality Leukocytosis, unspecified type   Leg pain, bilateral Bell's palsy
I started to break out in a rash about 2 hours after the shot.  By morning, it covered a large portion of behind my arm, back of legs, and knees.  I also had a racing pulse of over 110, severe headache, leg and foot cramping, loss of appetite, fever, a foggy feeling where I could not speak properly or keep my thoughts in line.
received the first dose of the Pfizer-BioNTech COVID-19 vaccine on 27Mar2021 and tested positive'; This is a spontaneous report from a contactable consumer. A 38-year-old male patient received  the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 27Mar2021 (Batch/Lot number was not reported) as an single dose for covid-19 immunization. The patient's medical history and  concomitant medications were not reported. The patient experienced received the first dose of the pfizer-biontech covid-19 vaccine on 27Mar2021 and tested positive on 01Apr2021. Patient explained he was symptom free and completed isolation and wanted to know if  okay for him to take his 2nd or he needs to reschedule. The outcome of the event was unknown.   Information on the lot/batch number has been requested.
inadvertently administered an expired Bexsero; This non-serious case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 16-year-old male patient who received Men B NVS (Bexsero) (batch number ABXC08AA, expiry date 31-MAR-2023) for prophylaxis.   On 10-APR-2023, the patient received Bexsero. On 10-APR-2023, an unknown time after receiving Bexsero, the patient experienced expired vaccine used (Verbatim: inadvertently administered an expired Bexsero). The outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 11-APR-2023 The Vaccine Coordinator enquired for any guidance on how to proceed?  The reporter did not consent to follow-up. The patient had inadvertently administered an expired Bexsero, which led to expired vaccine used.
beginning in the afternoon of  3FEB98 lt arm was very sore upon rising 5FEB98, red blotchy area noted below inj site, mid way between shoulder & elbow & anterior to inj site;tender;
Administration of expired vaccine. Expiration date: 8/7/22. Administration date: 8/16/22. No adverse symptoms reported.
congestion; allergies; headache; This spontaneous case was reported by a consumer and describes the occurrence of NASAL CONGESTION (congestion), HYPERSENSITIVITY (allergies) and HEADACHE (headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Feb-2021, the patient experienced NASAL CONGESTION (congestion), HYPERSENSITIVITY (allergies) and HEADACHE (headache). At the time of the report, NASAL CONGESTION (congestion), HYPERSENSITIVITY (allergies) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment information was provided.
Tingling in his right arm; A spontaneous report was received from a consumer concerning a 32-year-old, male patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced tingling in his right arm/paraesthesia.  The patient's medical history was not provided. No relevant concomitant medications were reported.    On 09-MAR-2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (lot/batch: unknown)  intramuscularly in the left arm for prophylaxis of COVID-19 infection.  On 11-MAR-2021, The patient experienced tingling in his right arm (paraesthesia).  Laboratory details were not provided.  No treatment information was provided.   Action taken with mRNA-1273 in response to the events was not reported.   On 11-MAR-2021 , the outcome of the event tingling in his right arm was unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Patient received a COVID-19 vaccine on 04MAR21 @ 1751, and, at 1815 he reported muscle pain in his left neck.  He described the pain as "slight pressure" in his left neck.  He was given Benadryl 50mg po and stayed an additional 15 minutes to be monitored.  Patient left at 1829 and stated that he felt "much better."
SORENESS REACTION IN ARM LASTED ABOUT THREE WEEKS; RECEIVED J&J VACCINE AS A  BOOSTER AFTER TWO DOSE OF PFIZER-BIONTECH COVID-19 VACCINE; This spontaneous report received from a patient via a company representative concerned a 69 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included: type ii diabetes, and other pre-existing medical conditions included: The patient had particular health issues. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 24-JUL-2021 for prophylactic vaccination. The batch number was not reported and has been requested. Concomitant medications included bnt 162 for prophylactic vaccination. On 24-JUL-2021, the patient experienced received j&j vaccine as a booster after two dose of pfizer-biontech covid-19 vaccine. On an unspecified date, the patient experienced soreness reaction in arm lasted about three weeks. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from soreness reaction in arm lasted about three weeks, and the outcome of received j&j vaccine as a booster after two dose of pfizer-biontech covid-19 vaccine was not reported. This report was non-serious.
Friday 4/23 evening: stomach turning began; evening stomach pain intensified; Saturday 4/24: diarrhea began; severe abdominal pain began; abdominal pain intensified with food ; Sunday 4/25 to Monday 4/26: diarrhea and abdominal pain persisted; Tuesday 4/27: diarrhea subsided; abdominal pain; Wednesday 4/28: abdominal pain; regular visit to nutrition response practitioner; supplement schedule adjusted; Thursday 4/29: abdominal pain; Friday 4/30: doctor?s appointment/exam; bloodwork taken; upon physical exam, suspected pancreatitis and prescribed limited diet (broths, crackers) and fluids and to hold on any supplements, prescribed omeprazole and sucralfate; Saturday 5/1: abdominal pain; ultrasound performed; bloodwork/labs did not show elevation of pancreatic enzymes, eosinophils much higher than normal (2,500); Sunday 5/2: abdominal pain persisted, worse when hungry; limited diet; Monday 5/3: abdominal pain; messaging with doctor; called pharmacist who administered vaccine to ask questions; pharmacist consulted with others and suggested to wait until end of six weeks for second dose to assess health at that time, said probably safe, but may cause same reaction with second dose; Tuesday 5/4: abdominal pain; messaging with doctor; Wednesday 5/5: abdominal pain; messaging with doctor; referral to dr. for consultation on endoscopy; suspected ulcer; visit to nutrition response practitioner; resumed limited supplements; Thursday 5/6 to 6/3: Managed pain with adjusted diet and supplements; over this time, consistent pain began to subside; able to add foods back to diet and reach a feeling of being "normal", lost weight; Friday 6/4: Six weeks since first vaccine, did not feel confident to take second dose; Monday 6/7: Called health department for guidance, was told I would have to start over again with first vaccine dose, and that doctor should have complete VAERS form.  Feeling better by this time, referral to doctor was made; Monday 7/12: Visited doctor and explained what happened, advised that the situation sounded like enteritis as an immune response to the vaccine; second dose would likely cause similar response.
This is in follow-up to report (s) previously submitted on 9/24/2008 Information has been received from a registered nurse concerning a 71 year old female with arthritis, bronchitis, hypertension, acute back pain, hypothyroidism, sulfonamide allergy and shellfish/iodine allergy who on 07-JUL-2008 was vaccinated subcutaneously with a 0.65 mL dose of ZOSTAVAX (lot # 659672/0294X). Concomitant therapy included BENICAR, CRESTOR, LASIX, and SYNTHROID. On 13-JUL-2008, the patient experienced a cold sore, headache and an enlarged lymph node. The patient called the practice. The patient was recovering. No product quality complaint was involved. Additional information has been requested. Follow-up information was received from physician's office notes and a registered nurse (R.N.) who reported a 71 year old white female with sinus disorder and a history of positive chicken poz titer, measles adn rubella disease, hepatitis A and B (1995) and influenza vaccinations (2007) who on 07-JUL-2008 was vaccinated subcutaneously with a 0.65 ml dose of  ZOSTAVAX vaccine (Oka/Merck) (lot # 659672/0294X) in the left deltoid. Concomitant therapy included CELEBREX and methadone hydrochloride. There was no illness at time of vaccination. The patient had headache one to two days after vaccine that now had subsided and developed cold sore on right side of lip on 13-JUL-2008, with some swelling right lymph node/neck. No inflammation at site of injections (left side). The patient was counseled that she should refrain from taking VALTREX for 14 days after vaccination. The patient was advised to use topical creams, cold compresses. The patient started taking VALTREX on 15-JUL-2008, despite advice otherwise. The patient stated right side of face was swollen and very slight rash note on neck. The patient took VALTREX for ten days, then the rash disappeared and cold sore very small when VALTREX discontinued. On 24-JUL-2008, the physician's office called the patient regarding follow up after shingles and the cold sore and left a message. The physician discussed the lack of protection from shingles due to taking an antiviral medication before 14 days. Additional information has been requested.
Headache, chills, fever 100.6 °F, fatigue; acetaminophen 500mg; symptoms abated 24h after vaccination
receiving covid 19 vaccine, encouraged to notify MD. currently taking celebrex or advil for pain; This is a spontaneous report from a contactable other hcp. A 56-years-old female patient received bnt162b2 (BNT162B2), Formulation: Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. On an unspecified date, the patient experienced  pain after receiving vaccine, encouraged to notify md. currently taking celebrex or advil for pain. Therapeutic measures were taken. The outcome of event was unknown.  Follow-up attempts have been completed and no further information is expected.